SCHEDULE 13D/A: Redmile Group Amends Atara Biotherapeutics Stake

Redmile Group, LLC and its affiliates filed an amended Schedule 13D for Atara Biotherapeutics, Inc., updating beneficial ownership to 9.9% and adding Redmile Strategic Long Only Trading Sub, Ltd. as a reporting person.

Summary

• Redmile Group, LLC and its affiliates (Jeremy C. Green, RedCo I, L.P., Redmile Biopharma Investments II, L.P., and Redmile Strategic Long Only Trading Sub, Ltd.) filed an Amendment No. 1 to their Schedule 13D for Atara Biotherapeutics, Inc.
• The amendment adds Redmile Strategic Long Only Trading Sub, Ltd. as a reporting person.
• Redmile Group, LLC and Jeremy C. Green beneficially own 751,223 shares, representing 9.9% of Atara Biotherapeutics' common stock.
• This ownership includes 441,701 directly held shares and 309,522 shares issuable upon warrant exercise, limited by a 9.99% beneficial ownership blocker.
• The total shares outstanding for Atara Biotherapeutics, Inc. were 7,210,235 as of November 6, 2025.
• RedCo I, L.P. beneficially owns 347,442 shares (4.7%), Redmile Biopharma Investments II, L.P. owns 452,153 shares (6.0%), and Redmile Strategic Long Only Trading Sub, Ltd. owns 376,377 shares (5.0%).
• No transactions in Atara Biotherapeutics' securities have occurred since the prior Schedule 13D filing.
• RedCo I ceased to be a 5% beneficial owner when Atara Biotherapeutics reported an increase in its outstanding Common Stock in its Form 10-Q filed on November 12, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is an administrative update to beneficial ownership, not indicative of new investment or divestment. The continued significant stake by Redmile Group is a stable signal, but the cessation of RedCo I as a 5% owner (due to dilution, not sale) is a minor negative.

Positives

• Continued significant investment by Redmile Group, indicating ongoing confidence in Atara Biotherapeutics.
• The existence of pre-funded warrants suggests a prior capital infusion into Atara Biotherapeutics.

Negatives

• RedCo I ceased to be a 5% beneficial owner, which could be interpreted as a slight reduction in its relative stake, although it is due to an increase in the issuer's outstanding shares, not a sale.

Risks

• The 9.99% Beneficial Ownership Limitation restricts the immediate exercise of all warrants, potentially limiting Redmile's ability to fully convert its investment into common stock without a 61-day notice period.
• Changes in the Issuer's outstanding common stock can impact the reported percentage of ownership for investors holding warrants with beneficial ownership blockers.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Atara Biotherapeutics' future performance or strategic direction. It solely reports changes in beneficial ownership by an investment group.

Industry Context

This filing reflects ongoing investment activity by specialized biopharma investment funds like Redmile Group in the biotechnology sector. The use of pre-funded warrants and beneficial ownership limitations is a common strategy for institutional investors to manage their stake and regulatory reporting requirements in growth-oriented companies like Atara Biotherapeutics.

Comparison to Industry Standards

• The 9.99% beneficial ownership limitation is a standard practice for institutional investors to avoid triggering certain regulatory thresholds (e.g., becoming an "insider" or requiring more extensive reporting) while maintaining a significant stake.
• Redmile Group's continued holding of a substantial stake (9.9%) in Atara Biotherapeutics is consistent with long-term investment strategies seen in the biotech sector, where significant capital is often required for drug development.
• The structure of investment through various funds (RedCo I, RBI II, Redmile Long Only) managed by a single entity (Redmile Group, LLC) is a common approach for large investment firms to diversify and manage their portfolios.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's holdings and structure. The continued holding by Redmile Group may be viewed positively as a sign of institutional confidence.
• Company (Atara Biotherapeutics): Awareness of a major shareholder's position and the terms of their warrant holdings.

Next Steps

• Redmile Group and its affiliates will continue to monitor their investment in Atara Biotherapeutics, Inc.
• The Beneficial Ownership Limitation may be changed by a holder upon 61 days' notice to the Issuer.

Key Dates

Recommendation

This Schedule 13D amendment is primarily an administrative update, reflecting changes in reporting structure and the impact of the issuer's increased outstanding shares on percentage ownership, rather than new investment or divestment activity. The reporting persons explicitly state no transactions have occurred since the prior filing. Therefore, it does not provide new fundamental information to warrant a change in investment recommendation; a 'hold' stance is appropriate as the underlying investment thesis for Atara Biotherapeutics remains unchanged by this filing.

Keywords

Atara Biotherapeutics, Redmile Group, Schedule 13D, Beneficial Ownership, Warrants, Biotechnology, Investment Funds, SEC Filing, ATRA